TNG348
BRCA1/2-mutant cancers
Phase 1Active
Key Facts
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotech focused on discovering and developing precision oncology medicines based on synthetic lethality. The company has built a robust pipeline with multiple clinical-stage assets, including PRMT5 and CoREST inhibitors, targeting cancers with specific genetic alterations like MTAP deletion and STK11 mutations. Its integrated discovery platform combines CRISPR-based functional genomics with patient-derived data to systematically identify novel drug targets, positioning it at the forefront of next-generation cancer therapeutics.
View full company profile